Gefitinib showed no clear difference in progression‐free survival (PFS) compared with chemotherapy (moderate certainty).
Gefitinib leads to higher skin rash compared with chemotherapy (high certainty).
Gefitinib leads to lower constipation compared with chemotherapy (high certainty).
Gefitinib probably leads to lower fatigue compared with chemotherapy (moderate certainty).
Gefitinib leads to lower asthenia compared with chemotherapy (high certainty).
Gefitinib leads to lower neurotoxicity compared with chemotherapy (high certainty).
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).
Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).
Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).